DOI: 10.20945/2359-3997000000451
Arch Endocrinol Metab. 2022;66(2):269-71
Where you read:
Mohammad Esmatinia 1
https://orcid.org/0000-0001-8582-5658
Should read:
Mahdi Mottaghi 1
. 2022 Sep 8;66(4):587. doi: 10.20945/2359-3997000000520
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
Collection date 2022.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC10697647 PMID: 36074945
This corrects the article "Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment" on page 269.